- Home
- CPA vs AKRO Comparison
CPA vs AKRO Comparison
Compare CPA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPA
- AKRO
- Stock Information
- Founded
- CPA 1947
- AKRO 2017
- Country
- CPA Panama
- AKRO United States
- Employees
- CPA N/A
- AKRO N/A
- Industry
- CPA Air Freight/Delivery Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CPA Consumer Discretionary
- AKRO Health Care
- Exchange
- CPA Nasdaq
- AKRO Nasdaq
- Market Cap
- CPA 5.1B
- AKRO 3.7B
- IPO Year
- CPA 2005
- AKRO 2019
- Fundamental
- Price
- CPA $127.23
- AKRO $54.01
- Analyst Decision
- CPA Strong Buy
- AKRO Buy
- Analyst Count
- CPA 5
- AKRO 10
- Target Price
- CPA $159.80
- AKRO $73.56
- AVG Volume (30 Days)
- CPA 198.6K
- AKRO 4.2M
- Earning Date
- CPA 11-19-2025
- AKRO 11-07-2025
- Dividend Yield
- CPA 5.20%
- AKRO N/A
- EPS Growth
- CPA N/A
- AKRO N/A
- EPS
- CPA 15.36
- AKRO N/A
- Revenue
- CPA $3,475,113,000.00
- AKRO N/A
- Revenue This Year
- CPA $5.97
- AKRO N/A
- Revenue Next Year
- CPA $9.17
- AKRO N/A
- P/E Ratio
- CPA $8.18
- AKRO N/A
- Revenue Growth
- CPA N/A
- AKRO N/A
- 52 Week Low
- CPA $82.54
- AKRO $21.34
- 52 Week High
- CPA $130.00
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- CPA 58.82
- AKRO 67.91
- Support Level
- CPA $122.55
- AKRO $53.40
- Resistance Level
- CPA $126.82
- AKRO $54.31
- Average True Range (ATR)
- CPA 2.78
- AKRO 0.23
- MACD
- CPA -0.25
- AKRO -0.21
- Stochastic Oscillator
- CPA 79.26
- AKRO 67.40
About CPA Copa Holdings S.A.
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.